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Patients who later have a mild course of hantavirus
cardiopulmonary syndrome (HCPS) are more likely to
exhibit a high titer of neutralizing antibodies against Sin
Nombre virus (SNV), the etiologic agent of HCPS, at the
time of hospital admission. Because administering plasma
from patients who have recovered from HCPS to those in
the early stages of disease may be an advantageous form
of passive immunotherapy, we examined the neutralizing
antibody titers of 21 patients who had recovered from SNV
infection. Even 1,000 days after admission to the hospital,
6 of 10 patients had titers of 800 or higher, with one sam-
ple retaining a titer of 3,200 after more than 1,400 days.
None of the convalescent-phase serum samples contained
detectable viral RNA. These results confirm that patients
retain high titers of neutralizing antibodies long after recov-
ery from SNV infection.
H
antaviruses are negative-stranded RNA viruses of the
family  Bunyaviridae. At least 11 members of the
rodent-borne genus Hantavirus have been associated with
hantavirus cardiopulmonary syndrome (HCPS) or hemor-
rhagic fever with renal syndrome (HFRS) in humans (1).
Sin Nombre virus (SNV), the prototype etiologic agent of
HCPS, is carried by the deer mouse, Peromyscus manicu-
latus (2). While four other etiologic viruses cause HCPS in
North and Central America and at least two cause HPCS in
South America, SNV accounts for most of the >300 known
North American cases.
SNV is transmitted primarily by inhalation of contami-
nated aerosols of rodent urine, feces, or saliva. The first
symptoms appear 9–33 days later (3). After a prodromal
phase of 1 to 6 days, consisting of fever, myalgia, head-
ache, malaise, gastrointestinal disturbances, and thrombo-
cytopenia, hypotension or shock and acute pulmonary
edema develop in most patients (4). In practice, HCPS is
provisionally diagnosed in most patients, and they are
admitted to a hospital on the first day that pulmonary
edema occurs. In patients with fatal cases, death occurs
within 3 days after the onset of respiratory symptoms.
Because such a narrow window exists between presenta-
tion and lethal outcome, improving the outcome will like-
ly require rapid and decisive intervention, perhaps before
the ultimate severity of the disease is known for a particu-
lar patient. Since most deaths are caused by myocardial
dysfunction and hypoperfusion rather than hypoxia, some
investigators have recently begun to use the term han-
tavirus cardiopulmonary syndrome (HCPS) rather than the
previous term hantavirus pulmonary syndrome. 
Antibodies of at least the immunoglobulin (Ig) M class
are present from the earliest clinical stages of HCPS, and
IgG antibodies against either the nucleocapsid (N) or G1
glycoprotein antigen are present in most patients even in
the prodrome phase (5). Recently, we examined the kinet-
ics of the development of antibodies capable of in vitro
neutralization of SNV in patients with HCPS and found
that many patients had exceptionally high titers (≥800) of
such antibodies from the first day of clinical illness (6). In
addition, we found that patients who had a milder course
of disease had markedly higher titers of neutralizing anti-
bodies on admission than did those patients who later
exhibited a more severe infection. Because other acute
viral infections have been successfully treated with the
plasma of patients who had recovered from these diseases,
we are contemplating the use of such treatment for
patients with HCPS. Toward this end, we examined the
kinetics of the decay of neutralizing antibodies in patients
who had recovered from SNV infection 3 months to 5
years before.
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Study Participants
Patients were considered to have acute SNV infection
on the basis of the following serologic criteria: the pres-
ence of IgM and IgG antibodies directed against the SNV
N antigen  and the presence of IgG antibodies against the
viral G1 antigen. The latter marker is specific for infection
with SNV (7). A total of 21 samples were collected from
21 patients who were called back for reevaluation as part
of a study of the sequelae of HCPS caused by SNV (D.
Goade, unpub. data). Informed consent was obtained from
patients or their parents or guardians, and human experi-
mentation guidelines of the U.S. Department of Health and
Human Services and the University of New Mexico
Human Research Review Committee were followed in the
conduct of this research.
Focus Reduction Neutralization Test (FRNT)
The serum samples from HCPS patients were examined
by FRNT in at least duplicate analyses in 48-well tissue
culture plates (6). (We did not subject serum samples to
heat inactivation because previous studies had shown that
decomplementation did not significantly change the meas-
ured FRNT titers of a group of human or rodent serum
specimens with titers between 800 and 1,280 [C. Ye,
unpub. data].) Samples were serially diluted (1:50, 1:100,
1:200, 1:400, 1:800, 1:3,200, 1:12,800) and mixed with
equal volumes of approximately 45 focus-forming units
(ffu) of SNV strain SN77734 (8) for 1 h at 37°C before
incubation on Vero E6 cells. The dilution buffer consisted
of complete minimal essential medium (MEM;
Gibco/BRL, Grand Island, NY) containing 2.5% fetal
bovine serum (HyClone Laboratories, Logan, UT). After
adsorption for 1 h at 37°, the cells were washed in phos-
phate-buffered saline (PBS) and overlaid with medium
containing 1.2% methylcellulose for 7 days. The methyl-
cellulose layer was removed, and the cells were fixed with
100% methanol with 0.5% hydrogen peroxide. Viral anti-
gen was visualized by the addition of hyperimmune rabbit
anti-SNV N protein (1:5,000), followed by peroxidase
conjugated goat anti-rabbit IgG (Jackson Immuno
Research Laboratory, West Grove, PA) and DAB/metal
concentrate as substrate (Pierce Chemicals, Rockford, IL).
The neutralization activity of a patient’s serum specimen
was expressed as the maximum serum dilution that would
reduce the number of viral foci by 80% or more.
Reverse Transcription–Polymerase 
Chain Reaction (RT-PCR)
RT-PCR was conducted as described previously (8).
The nested protocol in question has a sensitivity of <10
copies of viral RNA per reaction when RNA is isolated
from cell-free materials such as serum (J. Botten, B.
Hjelle, unpub. data). The primers, which have been
described previously (8), were located near the 5′ terminus
of the gene encoding the SNV N antigen. Many sequences
spanning this region have been examined from SNV iso-
lates from throughout the United States and Canada, and
little variation has been detected (B. Hjelle, unpub. data).
In each case, RNAwas prepared from 100 µLof serum and
20% of the preparation was subjected to nested RT-PCR
analysis. 
Results
The Table shows the geographic origin, age range, sex,
and clinical score of each of the 21 patients. Patients trav-
eled to Albuquerque, New Mexico, as funds permitted
from the University of New Mexico’s Research Allocation
Committee. The patients were subjected to a battery of
clinical tests, including studies examining pulmonary,
renal, and hepatic function. The results of the clinical stud-
ies will be reported separately.
Serum samples were collected for virologic studies and
examined for residual viral RNA by RT-PCR and for neu-
tralizing antibodies. Although positive control RNAprepa-
rations produced amplification products as expected, no
viral RNA was detected in any of the patients’serum sam-
ples (data not shown). However, the serum samples exam-
ined continued to exhibit neutralizing antibodies at titers
ranging from 100 to 3,200 (Figure). No statistically signif-
icant relationship existed between neutralizing antibody
titers after the patient’s recovery from SNV infection and
the severity of the previous illness, nor did a relationship
exist between antibody titers and the use of extracorporeal
membrane oxygenation (ECMO) in our patient group.
Discussion
Although case-fatality ratios for HCPS have declined
since the initial description of the disease, probably reflect-
ing improved recognition of mild illness, therapeutic
options remain limited. The efficacy, if any, of antiviral
drugs such as ribavirin remains to be demonstrated.
Intensive care management of the manifestations of the
disease constitutes the primary method of clinical inter-
vention. At some centers, ECMO has been utilized in those
patients who exhibit hemodynamic or pulmonary instabil-
ity that is predictive of fatal outcome (10). (Six of our
patients underwent this procedure.)
Although treating patients with viral hemorrhagic
fevers with the plasma of patients who have recovered
from the disease is often proposed or discussed, rigorous
demonstration of its efficacy in humans or animals is often
lacking. Argentine hemorrhagic fever (AHF) due to Junín
virus and other arenaviral diseases are among the excep-
tions (11–14). The efficacy of convalescent-phase plasma
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protective substance contained therein was positively iden-
tified. With the advent of a test for neutralizing activity,
Argentine investigators retrospectively demonstrated a
correlation between the quantity of the neutralizing activi-
ty of plasma and the degree of protection afforded by its
infusion (12). 
The neutralizing activity of a dose of plasma is defined
by multiplying the reciprocal of the highest dilution that
would reduce the number of viral foci by 80% by the vol-
ume of the inoculum, in milliliters. Overall, the infusion of
convalescent-phase plasma containing antibodies to Junín
virus reduced deaths by approximately 90%. In a retro-
spective analysis, investigators showed that those patients
who received >2,000 U/kg of neutralizing antibodies
appeared to respond better than did those patients who
received 1,000–2,000 U (12).
Because HCPS is rare, the number of treatments that
can be independently examined through clinical trials
without delaying the identification of an effective interven-
tion is inherently limited. To determine whether a clinical
rationale exists for attempting passive immunotherapy for
HCPS with neutralizing antibodies, we first studied the
relationship between the titer of such antibodies on a
patients’ admission to the hospital and the clinical out-
come. That study showed a profound and inverse relation-
ship between antibody titer and disease severity (6).
It then became important to determine whether the
small number of patients who have recovered from SNV
infection might constitute a pool of plasma donors of suf-
ficient size to provide a stable source of plasma to treat
future patients. The study reported herein was initiated to
determine whether neutralizing antibodies persist for sub-
stantial periods after recovery from the disease. Results
indicate that the answer is affirmative but that not all
recovered patients are equally rich sources of neutralizing
antibodies.
Modern techniques for collecting plasma allow for con-
venient and low-risk preparation of 500–600 mL or more
of plasma from healthy donors; this can be repeated on
multiple occasions over several weeks. For that and other
reasons, each of those patients whose titers remained at
>800 represents a rather rich source of antibodies. If one
extrapolates from the experience of the Argentine investi-
gators in their treatment of AHF, a single 600-mL plasma
donation by a person with a neutralizing antibody titer of
800 can be used to treat two 80-kg (~175-lb) patients. A
patient such as the person whose titer was 3,200 could be
identified as a particularly valuable repeat donor, one
whose every donation could be divided and used to treat
eight new patients with HCPS.
Thus far, little or no overlap occurs among the behav-
ioral characteristics associated with HCPS and those asso-
ciated with infection by bloodborne pathogens such as
HIV or hepatitis C virus. Potential donors would be sub-
jected to the same battery of questions and tests for blood-
borne pathogens as would any other directed blood donors,
with the exception that donors would be allowed to donate
despite the history of hospitalization for HCPS and receipt
of blood products during ECMO therapy. Although we
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Table. Demographic and clinical characteristics of 21 patients with history of Sin Nombre virus infection  
Patient  Age at time of illness  Sex  Date admitted  Day serum collected  Location  Severity
b 
1  10  M  30 Mar 1999  589  NM  I 
2  44  F  4 Dec 1995  1789  NM  IIE 
3  28  F  5 Apr 1999  592  NM  0 
4  28  F  3 Apr 1999  566  WA  II 
5  42  M  15 Jun 1999  94  NM  I 
6  29  F  1 May 1998  1063  NM  I 
7  18  F  11 Aug 1998  512  CO  IIE 
8  44  F  29 Mar 1994  1627  NM  II 
9  43  M  1 Sep 2000  231  AZ  IIE 
10  41  M  20 Mar 1997  1436  KS  II 
11  39  F  6 Mar 2001  85  NM  II 
12  50  M  20 Aug 1998  334  NM  IIE 
13  34  F  15 Jul 1999  92  CO  I 
14  44  F  3 Nov 1997  1281  KS  II 
15  19  F  18 Oct 2000  132  MT  II 
16  27  M  23 Jul 1997  1356  NM  I 
17  27  F  27 Jan 1998  1196  KS  I 
18  23  F  30 Oct 1999  161  NM  IIE 
19  16  M  19 Sep 1997  1419  TX  II NO (9) 
20  21  F  27 May 1994  2268  NM  II 
21  44  M  20 Dec 1997  1056  WI  II 
aF, female; M, male; NM, New Mexico, WA, Washington, CO, Colorado; AZ, Arizona; KS, Kansas; MT, Montana; TX, Texas; WI, Wisconsin. 
bSeverity scale: Class 0, prodromal symptoms with seroconversion but with no cardiopulmonary manifestations; Class I, prodrome symptoms with hypoxia but not 
requiring endotracheal intubation; Class II, survived but required endotracheal intubation; Class IIE, required extracorporeal membrane oxygenation; II NO, treated with 
inhalational nitric oxide. Because they required endotracheal intubation, patients in Class II are regarded as having been more severely ill than those in Classes 0 and I. therefore expect that most potential donations of convales-
cent-phase plasma would be free of bloodborne pathogens,
ensuring that SNV has been completely cleared from the
blood is more difficult. Thus far, no evidence for a persist-
ent state of SNV infection in humans has been shown. In
fact, studies published to date show that in all cases that
could be evaluated, SNV is undergoing rapid clearance at
the time of clinical presentation (15). 
Although our RT-PCR data are reassuringly negative,
we cannot know whether a larger dose of convalescent-
phase plasma would contain infectious SNV. In fact, SNV
has never been cultivated from any human source, despite
attempts by multiple laboratories.
We believe that passive immunotherapy may be effica-
ceous if administered very early in the course of illness,
before the severity of a particular patient’s disease course
is known. To reduce the risk for accidental inoculation of
potential recipients of anti-SNV convalescent-phase plas-
ma, at least two strategies are possible. First, one could
impose a delay of 6 to 36 hours by requiring that potential
recipients have a positive specific test for SNV antibodies
before the plasma is administered. Alternatively, one could
impose either purification or viral inactivation procedures
for the antibodies or await the development of human or
humanized monoclonal antibodies before instituting this
therapy. We presume in our risk analysis that no new risk
is associated with the inadvertent inoculation of a second
strain of SNV in a patient who is undergoing active infec-
tion with a different genotype of the same virus, since there
is no a priori evidence to suggest otherwise. 
No current evidence suggests that infusing anti-SNV
antibodies would enhance the pathogenesis of SNV. The
data of Bharadwaj et al. (6), in fact, support the presump-
tion that treatments that lead to higher titers of neutralizing
and even nonneutralizing anti-SNV antibodies are more
likely to lead to less severe disease. We believe that conva-
lescent-phase plasma therapy may represent a practical
intervention that is feasible, given current resources and
funding levels for potential antihantavirus therapies.
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